1、Unfolding The Future Of Biopharma2026SCRIP ASIA 100 3 Copyright 2025 Pharma Intelligence UK Limited(Citeline),a Norstella company(Unauthorized photocopying prohibited)2 SCRIP ASIA 100Copyright 2025 Pharma Intelligence UK Limited(Citeline),a Norstella company(Unauthorized photocopying prohibited)Whil

2、e the biopharma industrys attention globally this year has been mainly directed towards the US and what policies President Donald Trump may,or may not,implement,the Asia Pacific region continues to present multiple opportunities and is an increasingly important source of innovative drugs.The headlin

3、e theme since last years Scrip Asia 100 has undoubtedly been Chinas continued rapid emergence as a global R&D powerhouse.As of early 2025,close to 1,500 new drugs were in Chinese development,rapidly surpassing the USs total,while Chinese companies accounted for over a third of all the first launches

4、 of new active substances globally.The top two in terms of number of NAS launches were both Chinese companies,which also dominated the top 10 ranking in Citelines Pharma R&D Annual Review,based on data to the beginning of this year.The pace of deals under which major multinationals licensed either g

5、lobal or selected rights to assets originated by Chinese companies has accelerated so far in 2025,with one of the biggest alliances including a potential$12bn tie-up between GSK and Hengrui in July.According to some analyses,fully a third of licensing agreements(by deal value)came from China in the

6、first half of 2025,versus just single-digit percentages only a few years ago.But the story was not entirely about China.The Citeline data also showed South Korea was the third most common base for all companies globally reporting active R&D.Indeed,Korean companies struck several sizeable cross-borde